Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Off-Label Opioid Promotion: US FDA ‘Does Not Object’ To Intranasal Deterrence Data, Egalet Says

Mar 31 2017

• By Sue Sutter

Opioid abuse epidemic concept

Related Content

Abuse Deterrence: US Exclusivity Update May Ride User Fee Coattails

Mar 28 2017

Off-Label Communication: When Does It Align With Approved Labeling?

Jan 18 2017

Abuse-Deterrent Opioids: US FDA Follows The ‘Route Of Abuse’ To Exclusivity

Feb 27 2017

Egalet's Bid For Arymo ER Intranasal Abuse-Deterrence Claim Blocked By MorphaBond Exclusivity

Jan 11 2017

First Amendment Does Not Block Off-Label Enforcement Actions, FDA Reiterates

Jan 22 2017

Off-Label Preclearance Process Eyed As Potential Fix For FDA's Policy Dilemma

Mar 14 2016

FDA Panel Nod For Egalet Opioid's Deterrence Claims Made Easier By Tablet Hardness

Aug 05 2016

Related Companies

Zyla Life Sciences

Inspirion Delivery Technologies LLC

Amarin Corp plc

Daiichi Sankyo Co., Ltd.

Additional Topics

United States Advertising, Marketing & Sales Legal Issues Regulation BioPharmaceutical Neurology

More from Marketing & Advertising

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window